FibroGen, a biotech backed by Astellas and AstraZenec developing therapies for anemia and fibrosis, raised $146 million by offering 8.1 million shares at $18, toward the top of the $16 to $19 range. FibroGen plans to list on the NASDAQ under the symbol FGEN. Goldman Sachs, Citi and Leerink Partners acted as lead managers on the deal.
Feeling anemic? Biotech FibroGen prices IPO at $18, toward the top of the range
November 13, 2014
